| A linear model for transcription factor binding affinity prediction in protein binding microarrays M Annala, K Laurila, H Lähdesmäki, M Nykter PloS one 6 (5), e20059, 2011 | 66 | 2011 |
| A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer: Canadian cancer trials group study IND205 SJ Hotte, KN Chi, AM Joshua, D Tu, RJ Macfarlane, RW Gregg, ... Clinical Genitourinary Cancer 17 (3), 201-208. e1, 2019 | 35 | 2019 |
| A prostate cancer susceptibility allele at 6q22 increases RFX6 expression by modulating HOXB13 chromatin binding Q Huang, T Whitington, P Gao, JF Lindberg, Y Yang, J Sun, MR Väisänen, ... Nature genetics 46 (2), 126-135, 2014 | 228 | 2014 |
| Activating AKT1 and PIK3CA mutations in metastatic castration-resistant prostate cancer C Herberts, AJ Murtha, S Fu, G Wang, E Schönlau, H Xue, D Lin, ... European urology 78 (6), 834-844, 2020 | 72 | 2020 |
| Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors D Quigley, JJ Alumkal, AW Wyatt, V Kothari, A Foye, P Lloyd, R Aggarwal, ... Cancer discovery 7 (9), 999-1005, 2017 | 265 | 2017 |
| AR and ERG drive the expression of prostate cancer specific long noncoding RNAs A Kohvakka, M Sattari, A Shcherban, M Annala, A Urbanucci, J Kesseli, ... Oncogene 39 (30), 5241-5251, 2020 | 9 | 2020 |
| Biallelic tumour suppressor loss and DNA repair defects in de novo small‐cell prostate carcinoma ECP Chedgy, G Vandekerkhove, C Herberts, M Annala, AJ Donoghue, ... The Journal of pathology 246 (2), 244-253, 2018 | 46 | 2018 |
| BRCA2, ATM, and CDK12 Defects Differentially Shape Prostate Tumor Driver Genomics and Clinical Aggression E Warner, C Herberts, S Fu, S Yip, A Wong, G Wang, E Ritch, AJ Murtha, ... Clinical Cancer Research 27 (6), 1650-1662, 2021 | 71 | 2021 |
| Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial M Annala, S Fu, JVW Bacon, J Sipola, N Iqbal, C Ferrario, M Ong, ... Annals of Oncology 32 (7), 896-905, 2021 | 51 | 2021 |
| Circulating tumor DNA abundance and potential utility in de novo metastatic prostate cancer G Vandekerkhove, WJ Struss, M Annala, HML Kallio, D Khalaf, ... European urology 75 (4), 667-675, 2019 | 175 | 2019 |
| Circulating tumor DNA genomics correlate with resistance to abiraterone and enzalutamide in prostate cancer M Annala, G Vandekerkhove, D Khalaf, S Taavitsainen, K Beja, ... Cancer discovery 8 (4), 444-457, 2018 | 468 | 2018 |
| Circulating tumor DNA in patients with metastatic urothelial cancer: concordance of genomic findings with matched tissue biopsies. JM Lavoie, G Vandekerkhove, M Annala, N Sundahl, T Sano, WJ Struss, ... Journal of Clinical Oncology 37 (15_suppl), e16036-e16036, 2019 | 4 | 2019 |
| Circulating tumor DNA reveals clinically actionable somatic genome of metastatic bladder cancer G Vandekerkhove, T Todenhöfer, M Annala, WJ Struss, A Wong, K Beja, ... Clinical cancer research 23 (21), 6487-6497, 2017 | 152 | 2017 |
| Clinical association analysis of ependymomas and pilocytic astrocytomas reveals elevated FGFR3 and FGFR1 expression in aggressive ependymomas B Lehtinen, A Raita, J Kesseli, M Annala, K Nordfors, O Yli-Harja, ... BMC cancer 17, 1-12, 2017 | 24 | 2017 |
| Concordance of circulating tumor DNA and matched metastatic tissue biopsy in prostate cancer AW Wyatt, M Annala, R Aggarwal, K Beja, F Feng, J Youngren, A Foye, ... JNCI: Journal of the National Cancer Institute 109 (12), djx118, 2017 | 391 | 2017 |
| Constitutively active androgen receptor splice variants AR-V3, AR-V7 and AR-V9 are co-expressed in castration-resistant prostate cancer metastases HML Kallio, R Hieta, L Latonen, A Brofeldt, M Annala, K Kivinummi, ... British journal of cancer 119 (3), 347-356, 2018 | 95 | 2018 |
| Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer C Herberts, M Annala, J Sipola, SWS Ng, XE Chen, A Nurminen, ... Nature 608 (7921), 199-208, 2022 | 102 | 2022 |
| Detection of circulating tumor DNA in de novo metastatic castrate sensitive prostate cancer WJ Struss, G Vandekerkhove, M Annala, KN Chi, ME Gleave, A Wyatt Annals of Oncology 29, viii273, 2018 | 2 | 2018 |
| Detection of circulating tumor DNA in patients with metastatic clear cell renal cell carcinoma. L Nappi, J Bacon, M Annala, M Soleimani, JM Lavoie, KN Chi, AW Wyatt, ... Journal of Clinical Oncology 37 (15_suppl), e16105-e16105, 2019 | 1 | 2019 |
| DOT1L‐HES6 fusion drives androgen independent growth in prostate cancer M Annala, K Kivinummi, K Leinonen, J Tuominen, W Zhang, T Visakorpi, ... EMBO Molecular Medicine 6 (9), 1121-1123, 2014 | 16 | 2014 |